Therapeutic effect of mizoribine on pemphigus vulgaris and pemphigus foliaceus.

Authors:
Takashi Hashimoto
Takashi Hashimoto
Kurume University Institute of Cutaneous Cell Biology
Kurume | Japan
Tamihiro Kawakami
Tamihiro Kawakami
St Marianna University School of Medicine
Japan
Hiroshi Koga
Hiroshi Koga
Kurume University School of Medicine
Kurume | Japan
Bungo Ohyama
Bungo Ohyama
Kurume University School of Medicine
Japan
Takahiro Hamada
Takahiro Hamada
Kurume University School of Medicine
Japan
Teruki Dainichi
Teruki Dainichi
Kyoto University Graduate School of Medicine
Kyoto | Japan
Takekuni Nakama
Takekuni Nakama
Kurume University School of Medicine
Shinichiro Yasumoto
Shinichiro Yasumoto
Kurume University School of Medicine

Dermatol Ther 2012 Jul-Aug;25(4):382-5

Department of Dermatology, Kurume University School of Medicine and Kurume University Institute of Cutaneous Cell Biology, Kurume, Japan.

We evaluated the effectiveness of mizoribine, a newly developed immunosuppressive agent, as an adjuvant therapy in the treatment of both pemphigus vulgaris and pemphigus foliaceus. Eleven pemphigus patients (eight pemphigus vulgaris and three pemphigus foliaceus) received the combination therapy of prednisolone and mizoribine. Complete remission was observed in three of the eight patients with pemphigus vulgaris and in one of the three patients with pemphigus foliaceus. The four patients with complete remission had a rapid clinical response and achieved remission at a median of 11.8 months. Partial remission was achieved in two of the three patients with pemphigus foliaceus. The median time to achieve partial remission was 16.0 months. Six (55.6%) of the 11 patients with pemphigus had complete or partial remission and were able to taper their prednisolone. The cumulative probability of having a complete remission was 64.3% at 19 months of follow-up using Kaplan-Meier analysis. The effectiveness of the additional mizoribine therapy could be attributed to its corticosteroid-sparing properties as well as its immunosuppressive effects. The serum concentration titer of mizoribine was around 1.0 μg/mL 2 hours after administration. Patients who were not improved by the additional mizoribine might require a continuously higher dose of mizoribine to achieve effective therapy.

Download full-text PDF

Source
http://doi.wiley.com/10.1111/j.1529-8019.2012.01469.x
Publisher Site
http://dx.doi.org/10.1111/j.1529-8019.2012.01469.xDOI Listing

Still can't find the full text of the article?

We can help you send a request to the authors directly.
March 2013
1 Read

Publication Analysis

Top Keywords

pemphigus foliaceus
20
patients pemphigus
20
pemphigus vulgaris
16
complete remission
12
three patients
12
partial remission
12
pemphigus
11
vulgaris three
8
additional mizoribine
8
vulgaris pemphigus
8
remission
7
patients
7
mizoribine
6
foliaceus
5
complete partial
4
643% months
4
mizoribine achieve
4
remission taper
4
pemphigus complete
4
prednisolone cumulative
4

Similar Publications